Effect of neoadjuvant chemotherapy on ER, PR, c-erb2, VEGF and Ki-67 in patients with locally advanced breast cancer
Öz
Purpose: The aim of this study is aimed to demonstrate the changes in the tumor diameter and expressions of vascular endothelial growth factor (VEGF), estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Cerb-B2 status after neoadjuvant chemotherapy in the patients with locally advanced breast cancer.
Materials and Methods: Sixty-nine patients who diagnosed with locally advanced breast cancer and treated with were prospectively evaluated. The tumor diameter and VEGF, Ki-67, ER, PR, and Cerb-B2 expressions tested by immunohistochemistry (IHC) were evaluated before and after neoadjuvant chemotherapy.
Results: There was a statistically significant reduction in the tumor diameter and in the expression of VEGF, Ki-67, ER, PR, and Cerb-B2 after neoadjuvant chemotherapy.
Conclusion: The significant reduction in VEGF expression suggests that the tumor angiogenesis and its metastatic ability may be reduced by neoadjuvant chemotherapy. The significant change in the Ki-67 proliferation index may suggest the reduced proliferative activity of malignant cells with neoadjuvant chemotherapy.
Anahtar Kelimeler
Kaynakça
- 1. Jatoi I. Breast cancer: a systemic or local disease? Am J ClinOncol 1997; 20(5):536-9.
- 2. Güler N, Karabulut B, Koçdor MA, Kaya H, Esen G, Özaslan C, Saip P, Görken İ. Locally Advanced Breast Cancer-2010 Istanbul breast cancer Consensus Meeting. The Journal of Breast Health 2011:7(2);68-85.
- 3. Edge SB, Byrd DR, Compton CC, Fritz AG, Grene FI, Trotti A (Eds). Breast in AJCC Cancer Staging Manual. Seventh Edition. Springer, Chicago, IL 2010:345-377
- 4. Kim EA, Gershtein ES, Vyotskaya IV, Kushlinskii NE. Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bull Exp Biol Med. 2008;145(2):245-8.
- 5. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson D. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92(1):147-55.
- 6. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 2005;446(5):489-96
- 7. Matsubara N, Mukai H, Fujii S, Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer . Brest Can Res Treat 2013;137(1):203-12.
- 8. Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. JBUON 2013;18(2):366-71
- 9. Colleoni M, Giuseppe V, David Z. Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment. Clin Cancer Research 2004:10;6622-6628
- 10. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003:10;88(3):406-12
